Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab in Psoriatic Arthritis
NCT02029495Phase 3Terminated
- Sponsor
- Valeant Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of brodalumab in psoriatic arthritis (PsA), sponsored by Valeant Pharmaceuticals. Started Mar 2014; status: terminated.
02
Drugs
brodalumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02029495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029495.